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ABSTRACT
Background    Clarithromycin is a macrolide antibiotic 
that possesses anti-inflammatory and immunomodu-
latory properties. Although recent data suggests that 
macrolide antibiotics enhance Pseudomonas aeruginosa 
clearance from the lung, involving natural killer (NK) T 
cells in this process by activating the NKG2D-NKG2D 
ligand system, the precise underlying mechanism is still 
unclear. In this study, we examined the effect of clar-
ithromycin on a potent NKG2D ligand, UL16-binding 
protein 2 (ULBP2), in the lung and its shedding mecha-
nism.
Methods    The gene expressions of ULBP2 and the 
shredder proteinases of ULBP2, a disintegrin and metal-
loproteinase domain 10 (ADAM10) and ADAM17, were 
measured using real-time PCR. The cell surface ULBP2 
expression was measured by flow cytometry. The 
amount of solubilized ULBP2 (sULBP2) was measured 
using an ELISA. The activity of ADAM17 was exam-
ined by measurement of fluorescence intensity from the 
fluorescence resonance energy transfer peptide substrate 
cleaved by ADAM17.
Results    Clarithromycin significantly induced tran-
scription of ULBP2 and ADAM17 in both A549 and 
LCSC #2 cells, which endogenously express minimal 
and abundant levels of ULBP2, respectively. How-
ever, there was no significant change on transcription 
of ADAM10. The same tendency was observed when 
LCSC #2 cells were treated with tumor necrosis factor-
alpha processing inhibitor-2 to inhibit ADAM17 activity. 
The amount of sULBP2 was significantly decreased in 
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Abbreviations: ADAM, a disintegrin and metalloproteinase do-
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binding epidermal growth factor-like growth factor; IL, inter-
leukin; MFI, mean fluorescence intensity; NK, natural killer; 
sULBP2, solubilized ULBP2; TAPI-2, TNF-alpha processing in-
hibitor-2; TGF, transforming growth factor; TNF, tumor necrosis 
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both A549 and LCSC #2 cells by treatment with clar-
ithromycin. Finally, clarithromycin significantly inhib-
ited the activity of ADAM17 in LCSC #2 cells. 
Conclusion    These findings suggest that clarithromy-
cin induces ULBP2 expression and reduces the amount 
of sULBP2, by possibly inhibiting the activity of the po-
tent ULBP2-shedding enzyme ADAM17. Because these 
changes in ULBP2 and sULBP2 levels could activate 
NKT cells, this finding might indicate a novel mecha-
nism by which clarithromycin improves the clearance of 
P. aeruginosa in chronic respiratory diseases.
Key words   a disintegrin and metalloprotease domain 
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Clarithromycin is a member of the macrolide antibiotic 
class, potent and well-established antimicrobials with 
14- and 15-member lactone rings that also possess anti-
inflammatory and immunomodulatory properties.1–3 The 
effect of clarithromycin is mainly attributed to inhibition 
of inflammatory cytokine and chemokine production. 
The most proverbial demonstrations of the anti-inflam-
matory and immunomodulatory effects of macrolide 
antibiotics were reported in the successful treatment of 
diffuse panbronchiolitis4 and cystic fibrosis.5 These suc-
cesses expanded the evaluation of macrolide antibiotics 
for the treatment of other chronic inflammatory diseases 
in the lung.6 
 Chronic infection of the lung by pathogens such as 
Pseudomonas aeruginosa is a life-threatening problem 
for patients with diffuse panbronchiolitis,7 cystic fibro-
sis8 and other chronic inflammatory lung diseases. Re-
cent data suggests that macrolide antibiotics enhanced 
the clearance of P. aeruginosa from lung, although they 
intrinsically do not have antimicrobial activity for this 
bacterium.9 This result is thought to be another benefi-
cial effect of macrolide antibiotics for the treatment of 
lung diseases; however, the precise mechanism of clar-
ithromycin-induced clearance of P. aeruginosa in these 
chronic diseases remains unclear.
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Table 1. Primers used in this study
 Amplicon 
 size 
Gene (bp) Sequences of primers 
ULBP2 108 Forward: ccgctaccaagatccttctg
  Reverse: ggatgacggtgatgtcatagc
ADAM10 60 Forward: atattacggaacacgagaagctg
  Reverse: tcaatcgctttaacatgactgg
ADAM17 69 Forward: cctttctgcgagagggaac
  Reverse: caccttgcaggagttgtcagt
GAPDH 66 Forward: agccacatcgctgagaca
  Reverse: gcccaatacgaccaaatcc
ADAM, a disintegrin and metalloproteinase domain; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; ULBP2, UL16-
binding protein 2. 
 Recent data also suggests that natural killer (NK) T 
cells play a central role in clearing P. aeruginosa from 
the lungs.10 NKT cells are a specialized type of T cell 
that share properties of both T cells and NK cells and 
are emerging as critical regulators of the immune re-
sponse to infectious agents.11, 12 Additionally, NKT cells 
are thought to play a role in managing human infections 
such as cystic fibrosis.13, 14 Previous studies showed that 
the activities of NKT cells, CD8+T cells and NK cells 
are tightly controlled by the activation receptor NKG2D 
that is expressed on the cell surface of these immune 
effector cells.15 The ligands for NKG2D are generally 
not expressed in normal cells, but their expression is in-
duced in infected16 or transformed17 cells that should be 
eliminated by the host immune system. NKG2D on the 
surface of immune effector cells recognizes its ligands 
expressed on the surfaces of target cells and subsequent-
ly augments the cytolytic activity of the immune effector 
cells to promote destruction and clearance of pathogen-
infected cells. In line with this, recent data suggests that 
expression of NKG2D contributes to the pulmonary 
clearance of P. aeruginosa.16, 18 Therefore, this NKG2D-
NKG2D ligand system is thought to play an essential 
role in host immunity during chronic lung infections.
 UL16-binding protein 2 (ULBP2) is one of the li-
gands for NKG2D that is expressed on infected human 
lung epithelial cells.19 Recently, we demonstrated that 
cell surface ULBP2 is released in soluble form from 
the surface and the resultant soluble ULBP2 (sULBP2) 
reduces the cytotoxic activity of human peripheral 
blood mononuclear cells.19 Therefore, ULBP2 on the 
cell surface and sULBP2 may have crucial but opposite 
effects on the infection immunity of NKT, CD8+T and 
NK cells in the lung. However, the effect of clarithro-
mycin on these molecules has not been explored. In the 
present study, we evaluated the effect of clarithromycin 
on ULBP2, sULBP2 and their candidate shedder pro-
teinase, a disintegrin and metalloproteinase domain 10 





A549 lung cancer cell lines were obtained from the 
RIKEN cell bank (Tsukuba, Japan). LCSC #2 lung can-
cer cell lines were provided by the Cell Resource center 
for Biomedical Research (Institute of Development, 
Aging and Cancer, Tohoku University, Sendai, Japan). 
A549 cells were maintained in Dulbecco’s Modified 
Eagles Medium (Wako, Osaka, Japan) with 10% heat-
inactivated fetal bovine serum (FBS), 50 units/mL 
penicillin and 50 units/mL streptomycin. LCSC #2 cells 
were maintained in RPMI 1640 (Wako) with 10% heat-
inactivated FBS, 50 units/mL penicillin and 50 units/mL 
streptomycin. Both cell lines were cultured in humidi-
fied air with 5% CO2 at 37 ˚C.
Reagents
Clarithromycin was obtained from Tokyo Chemical 
Industry (Tokyo, Japan). Tumor necrosis factor (TNF)-
alpha processing inhibitor-2 (TAPI-2) was obtained 
from Enzo Life Science (Farmingdale, NY). Anti-
ULBP2 (clone 165903) and recombinant ULBP2-Fc 
were obtained from R&D Systems (Minneapolis, MN). 
Anti-ULBP2 (BUMO1) was purchased from Bamomab 
(Munich, Germany) and goat anti-mouse IgG2a was pur-
chased from SouthernBiotech Associates (Birmingham, 
AL). Isotype control IgG2a was obtained from Sigma-
Aldrich (St. Louis, MO).
RNA extraction and cDNA synthesis
Total RNA was extracted from cells using a QIAGEN 
RNeasyPlus Mini Kit (Qiagen, Venlo, Netherlands) ac-
cording to the manufacturer’s instructions. RNA was 
dissolved in 50 mL of Rnase-free water and stored at 
–80 ˚C until use in a cDNA preparation reaction. An 
aliquot was removed to determine the concentration 
of RNA in a spectrophotometer at 260 nm. For cDNA 
synthesis, each 20 mL reaction contained 1 mg of total 
RNA, as described in the QIAGEN QuantiTect Reverse 
Transcription Kit (Qiagen). Synthesis of cDNA was 
performed in a TaKaRa PCR Thermal Cycler (TaKaRa, 
Kyoto, Japan) according to the following procedure: the 
RNA samples were incubated in gDNA Wipeout Buffer 
(Qiagen) at 42 ˚C for 2 min; Quantiscript Reverse Tran-
scriptase, Quantiscript RT Buffer and RT Primer Mix 
(Qiagen) were added and incubated at 42 ˚C for 15 min; 
and the reverse transcriptase was inactivated for 3 min at 
95 ˚C. The cDNA was stored at –30 ˚C until use in real-
time PCR. 
33
Effect of clarithromycin on ULBP2
Quantitative real-time PCR
A LightCycler 480 (Roche Diagnostics, Mannheim, 
Germany) was used for all quantitative PCRs. Table 
1 shows the gene-specific primers used. All PCR am-
plification reactions were performed with 0.5 mM 
forward primers, 0.5 mM reverse primers (Sigma-
Genosys, Ishikari, Japan), 0.4 mM hydrolysis probes for 
each target gene from a universal probe library (Roche 
Diagnostics), 1× LightCycler 480 Probes Master (Roche 
Diagnostics) and 4 mL diluted cDNA (1:10). The cy-
cling parameters used were as follows: one denaturation 
cycle for 600 s at 95 ˚C and 45 amplification cycles 
(temperature transition rate of 4.4 ˚C s–1) of 10 s at 95 
˚C, annealing for 25 s at 55 ˚C and extension for 1 s at 
72 ˚C. Fluorescence readings were taken after each cycle 
following the extension step. The LightCycler 480 soft-
ware generated a standard curve from the standards and 
determined the gene copy number in each test sample. 
Fig. 1. The effect of clarithromycin on the mRNA expression of ULBP2, ADAM10 and ADAM17 in A549 and LCSC #2 cell lines. 
A549 and LCSC #2 cells were treated with 0.1, 1 or 10 μg/mL clarithromycin for 24 h after serum starvation and harvested for total RNA 
extraction and quantitative real-time PCR. The ratios of gene expression between the target genes (ULBP2, ADAM10 and ADAM17) 
and internal standard (GAPDH) were expressed relative to those of A549 or LCSC #2 cells without clarithromycin treatment, which are 
set at 1.00. Data are expressed as mean values ± SD (n = 3 for each group). *P < 0.05 versus control. A: mRNA expression of ULBP2 in 
A549 cells. B: mRNA expression of ULBP2 in LCSC #2 cells. C: mRNA expression of ADAM10 in A549 cells. D: mRNA expression 
of ADAM10 in LCSC #2 cells. E: mRNA expression of ADAM17 in A549 cells. F: mRNA expression of ADAM17 in LCSC #2 cells. 
ADAM, a disintegrin and metalloproteinase domain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ULBP2, UL16-binding pro-
tein 2.  
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Fig. 2. The effect of clarithromycin on the cell surface expression 
of ULBP2 in A549 and LCSC #2 cell lines. A549 and LCSC #2 
cells were treated with or without 10 μg/mL clarithromycin or 
50 μM TAPI-2 for 24 h after serum starvation and harvested for 
flow cytometry. A: A549 cells treated with or without 10 μg/mL 
clarithromycin. B: LCSC #2 cells treated with or without 10 μg/
mL clarithromycin. C: A549 cells treated with or without 50 μM 
TAPI-2. D: LCSC #2 cells treated with or without 50 μM TAPI-
2. TAPI-2, TNF-alpha processing inhibitor-2; ULBP2, UL16-
binding protein 2.
The ratios of gene expression between the target genes 
(ULBP2, ADAM10, and ADAM17) and the internal 
standard (GAPDH) were expressed relative to those of 
A549 or LCSC #2 without clarithromycin, which is set 
at 1.00.
Flow cytometry
Cells were incubated with monoclonal anti-ULBP2 
antibodies or isotype controls. After washing, goat 
anti-mouse IgG labeled with FITC was added, and the 
fluorescence intensities of samples were analyzed on 
a FACSCalibur (BD Biosciences, La Jolla, CA). Data 
from 10,000 cells were collected, and the geometric 
mean fluorescence intensity (MFI) was calculated using 
CELLQuest software (BD Biosciences). MFI ratios were 
calculated by dividing the MFI obtained with a specific 
antibody by that for the isotype control.
ELISA
Two monoclonal anti-ULBP2 antibodies were used to 
detect sULBP2. Plates were coated with the anti-ULBP2 
mAb BUMO1 at 2 mg/mL in coating buffer for 24 h at 
4 ˚C, then blocked with blocking buffer for 18 h at 4 ˚C. 
The blocking buffer was prepared with a commercially 
available blocking agent (Applied Bioscience, Mumbai, 
India). Next, ULBP2-Fc (standard) and the samples were 
added, and the plates were incubated for 1 h at room 
temperature. For analysis of serum samples, ULBP2-Fc 
was diluted in blocking buffer with 25% horse serum, 
and sera were diluted 1:3 in blocking buffer before ad-
dition to the plates. After incubation, the detector mAb 
(anti-ULBP2, clone 165903) was added at 0.5 mg/mL 
in blocking buffer for 1 h at room temperature, followed 
by incubation with anti-mouse IgG2a-HRP (1:10,000 
in blocking buffer) for 1 h at 37 ˚C. Color was devel-
oped with a Sumilon peroxidase ELISA kit (Sumitomo 
Chemical, Tokyo), and the absorbance was read at 490 
nm on a Model 680 microplate reader (Bio-Rad Labora-
tories, Hercules, CA). 
 
TACE activity assay
The activity of ADAM17, which is also known as 
TACE, was determined using the SensoLyte 520 TACE 
Activity Assay Kit (AnaSpec, San Jose, CA) with 10 
µg of cell lysate proteins from each sample according 
to the manufacturer’s protocol. This assay uses a 5-car-
boxyfluorescein (5-FAM)-labeled fluorescence reso-
nance energy transfer (FRET) peptide substrate. Upon 
cleavage of the FRET peptide by the active enzyme, the 
fluorescence of 5-FAM is recovered and can be moni-
tored at excitation/emission wavelengths of 490/520 nm. 
Fluorescence of the cleavage product was measured in 
a fluorescence microplate reader (TECAN, Seestrasse, 
Switzerland). Results are expressed as the mean change 
in fluorescence intensity per min.
 
Statistical analysis
Statistical analyses were performed using the SPSS 21.0 
software (International Business Machines Corporation, 
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Fig. 3. The effect of clarithromycin on the level of sULBP2 in 
A549 and LCSC #2 cell lines. Measurement of sULBP2 in culture 
supernatants using ELISA. A549 and LCSC #2 cells were treated 
with or without 10 μg/mL clarithromycin for 24 or 72 h after 
serum starvation. After treatment, the culture supernatants were 
harvested for ELISA. Data are expressed as mean values ± SD (n 
= 3 for each group). *P < 0.05. A: A549 cells treated with or with-
out 10 μg/mL clarithromycin. B: LCSC #2 cells treated with or 
without 10 μg/mL clarithromycin. sULBP2, solubilized ULBP2.
Armonk, NY) and P < 0.05 was regarded as statistically 
significant.
RESULTS 
Effect of clarithromycin on ULBP2 mRNA expres-
sion
To evaluate the influence of clarithromycin on ULBP2 
and its shedding mechanism, we first assessed the ef-
fect of clarithromycin on mRNA expression of ULBP2, 
ADAM10 and ADAM17. We used two cell lines, A549 
and LCSC #2, which express ULBP2 at low and high 
levels, respectively. Transcript levels of ULBP2 were 
significantly up-regulated in A549 (Fig. 1A) and LCSC 
#2 (Fig. 1B) cells treated with 10 mg/mL clarithromycin 
for 24 h. Additionally, although there was no significant 
effect of clarithromycin on the mRNA expression of 
ADAM10 in A549 (Fig. 1C) or LCSC #2 (Fig. 1D) cells, 
ADAM17 mRNA expression was up-regulated in A549 
(Fig. 1E) and LCSC #2 (Fig. 1F) cells treated with 1 or 
10 mg/mL clarithromycin for 24 h. These data suggest 
that clarithromycin induces transcription of ULBP2 and 
ADAM17.
 
Effect of clarithromycin on cell surface and soluble 
ULBP2
Next, to identify the effect of clarithromycin on pro-
tein expression of ULBP2, we evaluated the changes 
of cell surface ULBP2 expression in A549 and LCSC 
#2 cells after 24 h treatment with or without 10 mg/mL 
clarithromycin (Figs. 2A and B). Although there was no 
significant difference of cell surface ULBP2 expression 
in A549 cells with or without 10 mg/mL clarithromycin 
treatment (Fig. 2A, MFI ratio: 1.13 versus 1.11, respec-
tively), the expression level of ULBP2 in LCSC #2 cells 
with 10 mg/mL clarithromycin was significantly higher 
than that without clarithromycin (Fig. 2B, MFI ratio: 
22.6 versus 11.5, respectively). To test the contribution of 
ULBP2 shedding to this change, we next examined the 
effect of TAPI-2, an ADAM17 inhibitor, on the expres-
sion of ULBP2. The same tendency was observed when 
LCSC #2 cells were treated with 50 mM TAPI-2 for 24 
h (Figs. 2C and D). Therefore, clarithromycin may mim-
ic the effect of TAPI-2, especially for cells with abun-
dant expression of ULBP2 such as LCSC #2 cells. These 
data suggest that clarithromycin induces cell surface 
ULBP2 expression. In addition, the mechanism of this 
effect is presumably induction of ULBP2 gene transcrip-
tion and inhibition of ULBP2 shedding by ADAM17.
Quantification of sULBP2
Previously, we showed that ULBP2 is shed into the cul-
ture medium in proportion to the level of its cell surface 
expression by non-small cell lung cancer cell lines.19 
Therefore, to reveal the effect of clarithromycin on 
sULBP2, we used ELISA to analyze culture superna-
tants from A549 (Fig. 3A) and LCSC #2 cells (Fig. 3B) 
at 24 and 72 h after treatment with or without clarithro-
mycin. The number of the cells did not differ significant-
ly under each experimental condition (data not shown); 
however, the amount of sULBP2 increased over time in 
these cell lines. The amount of sULBP2 with clarithro-
mycin was significantly decreased relative to that with-
out clarithromycin in both A549 and LCSC #2 cells (Figs. 
3A and B). These findings suggest an inhibitory effect of 
clarithromycin on the ULBP2 shedding mechanism.
 
Evaluation of ADAM17 activity
To explore the effect of clarithromycin on the ULBP2 
shedding mechanism, we next examined the effect of 
clarithromycin on the activity of ADAM17 because re-
duction of sULBP2 was observed despite increased tran-
scription of the shedder enzyme ADAM17. As shown in 
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Fig. 4, 10 mg/mL clarithromycin significantly inhibited 
the activity of ADAM17 in LCSC #2 cells with high 
cell surface ULBP2 expression. However, the effect of 
clarithromycin on A549 cells, which expressed lower 
levels of ULBP2, was not significant. This finding dem-
onstrates that clarithromycin inhibits ADAM17 activity 
and, consequently, the ULBP2 shedding mechanism. 
DISCUSSION
In this study, we examined the effect of clarithromycin 
on ULBP2 expression. Our results showed that clarithro-
mycin induced the transcription and expression of cell 
surface ULBP2 while reducing the amount of sULBP2 
in the culture medium. Additionally, clarithromycin in-
hibited the activity of ADAM17, a shedder enzyme for 
cell surface NKG2D ligands.21 Because immune effector 
cells such as NKT cells, CD8+T cells and NK cells are 
activated by enhanced expression of ULBP2 on the sur-
faces of target cells and are affected by only low levels 
of sULBP2, these pleiotropic effects of clarithromycin 
on ULBP2 expression might contribute to the enhanced 
function of immune effector cells, thereby augmenting P. 
aeruginosa clearance in the lung. 
 In this study, we first reported the up-regulation of 
ULBP2 and ADAM17 gene transcription in human cells 
derived from the lung. Previous studies reported that 
clarithromycin influences the gene expression of various 
proteins in human cells, including both reduction and in-
duction of genes involved in inflammation. For example, 
studies have shown that clarithromycin inhibited gene 
transcription of mucin,22 IL-8 23 and various cytokines 
such as TNF-alpha, interferon gamma, interleukin (IL)-2, 
IL-4, IL-5 and IL-6.24 On the other hand, transcription 
of IL-1025 and alpha1-acid glycoprotein was induced by 
clarithromycin in hepatocytes.26 Toward understand-
ing the mechanism of gene transcription modulation by 
clarithromycin, a previous study reported that clarithro-
mycin inhibits activator protein-1 transcription factor23 
or potentiates glucocorticoid response element.26 The 
precise mechanism leading to up-regulation of ULBP2 
and ADAM17 is still unclear, but it may occur through 
the modulation of certain transcription factors. Because 
most previous reports focused on the effect of clarithro-
mycin on the inflammatory cytokines, its effect on other 
proteins involved in the immune process and its mecha-
nism of action must be explored in future studies.
 In addition to its role in transcriptional regulation, 
we revealed that clarithromycin inhibits the enzymatic 
activity of ADAM17. The inhibitory effect of clar-
ithromycin on enzyme activity has been reported in 
other enzymes such as cytochrome P450 3A,27 human 
serum paraoxonase28 and glycosidase.29 This effect of 
clarithromycin on ADAM17 activity represents a new 
mechanism that may explain the recent reports of broad 
pleiotropic activities of macrolide antibiotics for immu-
nomodulatory,30 anti-inflammatory31 and antitumor32 ef-
fects. Previous studies revealed that ADAM17, originally 
identified as an enzyme that proteolytically cleaves pro-
TNF-alpha to generate soluble TNF-alpha,33 cleaves and 
solubilizes a wide range of membrane-bound proteins 
including transforming growth factor (TGF)-alpha34 and 
heparin-binding epidermal growth factor-like growth 
factor (HB-EGF).35 The substrate proteins of ADAM17 
make obvious contributions to various pathogeneses, for 
example, TNF-alpha is involved in inflammation, and 
both TGF-alpha and HB-EGF contribute to tumorigen-
esis. Therefore, inhibition of the activity of ADAM17 by 
clarithromycin might represent a novel mechanism for 
its effect on these pathological conditions.
 Recent reports suggested that P. aeruginosa infec-
tion induced the surface expression of human NKG2D 
ligands such as ULBP2 in airway epithelial cells and 
signified the indispensability of induced NKG2D-
mediated immune activation in the clearance of this 
bacterium.16, 18 In addition, we previously revealed that P. 
aeruginosa is actively involved in this process by secret-
ing a quorum sensing molecule, N-3-oxo-dodecanoyl 
homoserine lactone, that decreases cell surface ULBP2 
and increases sULBP2.36 This intervention by P. aerugi-
nosa leads to attenuation of the host NKG2D-mediated 
immune response and is beneficial for its survival in 
the human lung. Our novel finding in this study that 
Fig. 4. The effect of clarithromycin on ADAM17 activity in A549 
and LCSC #2 cell lines. ADAM17 activity was determined using 
the SensoLyte 520 TACE Activity Assay Kit with 10 µg of cell 
lysate proteins for each sample according to the manufacturer’s 
protocol. A549 and LCSC #2 cells were treated with or without 
10 μg/mL clarithromycin for 24 h after serum starvation and 
harvested for the assay. Data are expressed as the mean change in 
fluorescence intensity per min ± SD (n = 3 for each group). *P < 
0.05. ADAM, a disintegrin and metalloproteinase domain.
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clarithromycin increases the cell surface ULBP2 expres-
sion and decreases sULBP2 suggests a mechanism by 
which it counteracts the immunosuppressive activity of P. 
aeruginosa and might explain the effectiveness of clar-
ithromycin in treating chronic P. aeruginosa infection in 
chronic lung diseases.37
 In conclusion, we revealed that clarithromycin in-
duces expression of ULBP2 and, through ADAM17, re-
duces sULBP2. These findings suggest the possibilities 
that clarithromycin can activate NKT cells and decrease 
the colonization of bacteria in patients with chronic 
respiratory diseases such as diffuse panbronchiolitis. 
Therefore, further study toward augmenting the effect 
of clarithromycin on NKT cell activity through ULBP2 
might be useful for developing new macrolide-based 
treatments for chronic respiratory diseases.
The authors declare no conflict of interest.
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